Lisata Therapeutics (LSTA) Form 3 LISATA THERAPEUTICS / Tariq Imam ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Imam Tariq

(Last) (First) (Middle)

C/O LISATA THERAPEUTICS, INC.

110 ALLEN ROAD, 2ND FLOOR

(Street)

BASKING RIDGE NJ 07920

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/03/2025

3. Issuer Name and Ticker or Trading Symbol
LISATA THERAPEUTICS, INC. [ LSTA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP, Bus Dev, General Counsel

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	24,579(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	05/18/2017	01/09/2027	Common Stock	14	53.1	D
Stock Option (Right to Buy)	01/08/2021	01/08/2028	Common Stock	96	56.85	D
Stock Option (Right to Buy)	01/14/2022	01/14/2029	Common Stock	168	74.25	D
Stock Option (Right to Buy)	01/13/2023	01/13/2030	Common Stock	480	49.2	D
Stock Option (Right to Buy)	01/11/2024	01/11/2031	Common Stock	466	23.85	D
Stock Option (Right to Buy)	01/10/2025	01/10/2032	Common Stock	1,466	13.76	D
Stock Option (Right to Buy)	(2)	01/09/2033	Common Stock	3,000	3	D
Stock Option (Right to Buy)	(3)	01/09/2034	Common Stock	4,000	3.08	D
Stock Option (Right to Buy)	(4)	01/09/2035	Common Stock	5,000	3.8	D

Explanation of Responses:

1. Includes (i) 1, 375 restricted stock awards granted on January 9, 2023 and vesting in four equal annual installments beginning on the grant date, (ii) 4,000 restricted stock awards granted on January 9, 2024 and vesting in four equal annual installments beginning on the grant date, and (iii) 6,750 restricted stock awards granted on January 9, 2025 and vesting in four equal annual installments beginning on the grant date.

2. This option was granted on January 9, 2023 and vests in four equal annual installments beginning on the grant date.

3. This option was granted on January 9, 2024 and vests in four equal annual installments beginning on the grant date.

4. This option was granted on January 9, 2025 and vests in four equal annual installments beginning on the grant date.

Remarks:

Senior Vice President, Business Development & General Counsel Exhibit 24.1 - Power of Attorney

	Tariq Imam	02/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.